Target intelligence / Profile preview

Myozenin-1 (MYOZ1)

Target
MYOZ1
Molecular classification
Other (Z-disc structural protein; sarcomeric protein; adapter protein), Not classified as receptor, ion channel, enzyme, transporter, or transcription factor
01

Overview

Myozenin-1 (MYOZ1, also known as calsarcin-2) is a Z-disc structural and adapter protein highly expressed in skeletal muscle and to a lesser extent in cardiac tissue[1][3][5]. It binds multiple Z-disc proteins, including α-actinin, γ-filamin, and telethonin, and colocalizes at the sarcomeric Z-line, serving as a molecular hub that stabilizes and organizes the contractile apparatus[1][2][4][5]. MYOZ1 also interacts with calcineurin, modulating its activity and thereby regulating the calcineurin/NFAT signaling pathway important for muscle fiber type differentiation and muscle growth[3][5]. Mutations in the MYOZ1 gene have been linked to various myopathies and cardiac hypertrophy, but do not appear to be major drivers of idiopathic dilated cardiomyopathy[1][3][5]. While MYOZ1 has clear biological roles in muscle structure and function, it is not considered a receptor, enzyme, transporter, or direct therapeutic target at present.

Other names
Calsarcin-2FATZCS-2Filamin-, actinin- and telethonin-binding proteinProtein FATZMYOZ
02

Mechanism of action

Null (as MYOZ1 is not a therapeutic target for drugs)

03

Biological functions

Structural assembly and stabilization of the sarcomeric Z-disc in cardiac and skeletal muscleBinding and linkage of Z-disc proteins including α-actinin, γ-filamin, telethonin, and LDB3/ZASPIntracellular tethering and modulation of calcineurin signaling (calcineurin/NFAT pathway)Regulation of skeletal muscle fiber type differentiation (fast vs. slow muscle fibers)Participation in myofibrillogenesis and muscle growth
04

Disease associations

Muscular dystrophy and neuromuscular myopathy (mutation-associated)Cardiac hypertrophyMyopathy, myofibrillar, 4Atrial standstill 1Generally structural rather than a primary therapeutic target or mutant driver in idiopathic dilated cardiomyopathy
05

Safety considerations

Null (no notable safety concerns as a direct therapeutic target, but mutations may be associated with neuromuscular disease or cardiac hypertrophy[3])
06

Interacting drugs

None identified in the provided sources or in standard drug databases as of June 2024. No approved therapeutics directly target MYOZ1.
07

Biomarkers

Null (no standard use as clinical biomarker for patient selection or efficacy monitoring)

Beyond the preview

Go deeper on Myozenin-1 (MYOZ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myozenin-1 (MYOZ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call